XPOVIO® is the first and only approved XPO1 inhibitor in Thailand. XPOVIO® has been approved for multiple indications in nine markets across the APAC region. Antengene has submitted a new dru
SHANGHAI,Sept. 23,2024-- On September 14,2024,BioCity presented interim clinical results on the safety and efficacy of its first-in-class antibody-drug conjugate (ADC) BC3195 targeting CDH3 (P-Cadheri
HONG KONG,Sept. 23,2024-- WuXi Biologics ("WuXi Bio") (2269.HK),a leading global Contract Research,Development and Manufacturing Organization (CRDMO),today announced that it has been include
GAOBEIDIAN,China,Sept. 23,2024-- On September 20,the 2024 China•Gaobeidian International Windoor Festival,alongside the 2024 China•Gaobeidian International Green and Healthy Building Conference,comm
Pitching Challenge to Reward Companies with United States Pilot and Funding Opportunities DALLAS,Sept. 23,2024--North Texas Innovation Alliance (NTXIA),a 501(c)3 regional consortium of over 40 munici
MADRID,Sept. 23,2024--During the recent G20 Tourism Ministers\' meeting inBelém,Brazil,UN World Tourism Organization Secretary-General,Zurab Pololikashvili,called for urgent measures to reshape
